Breaking News
-
EMA’s committee issues opinion to take measures to limit presence of nitrosamines in medicines
103 0EMA’s human medicines committee (CHMP) has issued an opinion requiring…
Read more -
IDEAYA Biosciences begins patient dosing in phase 1 combination study of IDE196 and binimetinib to treat MUM
130 0IDEAYA Biosciences, an oncology-focused precision medicine company committed to the…
Read more -
NIH researchers reframe dog-to-human aging comparisons
88 0One of the most common misconceptions is that one human…
Read more -
Philip Morris gets US FDA marketing nod for IQOS tobacco heating system with ‘reduced exposure’ information
151 2The US Food and Drug Administration (FDA) authorized the marketing…
Read more -
Sedana Medical phase III study of IsoConDa meets primary endpoint
130 0Sedana Medical AB (publ), a medical device company, announced a…
Read more -
Digital Pharma—Beyond the Pill. Digital medicines and digital health
142 1Digitalization is playing an increasingly important role in drug-development and…
Read more -
Pharma Business propels Beaufond PLC’s 3rd Quarter 62.16 % increase in EBITDA to USD 17.736 million of against USD 10.937 million to the corresponding period of last year.
124 0Beaufond PLC continues to pursue its development strategy and once…
Read more -
INOVIO, IVI & Seoul National University Hospital partner to begin phase 1/2 trial of INOVIO’s COVID-19 DNA vaccine in South Korea
127 0INOVIO, the International Vaccine Institute (IVI), and Seoul National University…
Read more -
Novartis phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair Breezhaler vs free combo of two existing inhaled treatments in uncontrolled asthma
291 0Novartis announced that full results from the phase IIIb ARGON…
Read more -
WHO welcomes crucial new funding for vaccines
78 0WHO welcomes funding commitments made at the Global Vaccine Summit,…
Read more